H. Lundbeck A/S
Lundbeck held its Annual General Meeting on 25 March 2015 at the company’s registered office

DGAP-News: H. Lundbeck A/S

2015-03-25 / 15:19

---------------------------------------------------------------------

Valby, Denmark, 25 March 2015 - H. Lundbeck A/S (Lundbeck) today announced that
at the Annual General Meeting the report by the Board of Directors was adopted
and the annual report was approved. 

Håkan Björklund, Lars Rasmussen and Terrie Curran were re-elected, while Lene
Skole, Jesper Ovesen and Lars Holmqvist were elected to the Board of Directors.
Christian Dyvig, Thorleif Krarup and Melanie Lee did not stand for re-election.
Immediately after the general meeting, the Board of Directors elected Håkan
Björklund as Chairman and Lene Skole as Deputy Chairman of the Board of
Directors. 

The Board of Directors of Lundbeck will hereafter comprise:

  -- Håkan Björklund (Chairman)
  -- Lene Skole (Deputy Chairman)
  -- Lars Rasmussen
  -- Terrie Curran
  -- Jesper Ovesen
  -- Lars Holmqvist
  -- Mona Elisabeth Elster (employee representative)
  -- Jørn Møller Mayntzhusen (employee representative)
  -- Henrik Sindal Jensen (employee representative)

After having elected its Chairman and Deputy Chairman, the Board of Directors
appointed members for the Audit Committee, the Remuneration Committee and the
Scientific Committee. 

Jesper Ovesen, Lars Rasmussen and Lars Holmqvist were elected as members of the
Audit Committee. Håkan Björklund, Lene Skole and Terrie Curran were elected as
members of the Remuneration Committee. Håkan Björklund and Lene Skole were
elected as members of the Scientific Committee. 

The General Meeting approved the remuneration for the Board of Directors for
2015. 

The General Meeting approved a separate fixed monthly salary to the Chairman
due to extended operational responsibilities. 

The General Meeting approved not to pay-out dividend.

Deloitte Statsautoriseret Revisionspartnerselskab was re-elected as the
company's auditor. 

The General Meeting authorized the Board of Directors to increase the share
capital by a nominal amount of up to DKK 100.000.000 with or without
pre-emption rights for the existing shareholders for a period until 25 March
2020. 

The proposal of the Board of Directors to adjust the company's 'Remuneration
guidelines for the Board of Directors and the Executive Management of H.
Lundbeck A/S' was approved. 

The proposal to give the Board of Directors authorization to let the company
acquire own shares of a total nominal value of up to 10% of the share capital
was adopted. 

The Chairman of the General Meeting was authorized to adopt the amendments and
register with the Danish Business Authority. 

No other business was handled at the Annual General Meeting.

The Board of Directors



Lundbeck contacts



Investors:                          Media:                   
                                                             
Palle Holm Olesen                   Mads Kronborg            
Vice President, Investor Relations  Director, Media Relations
palo@lundbeck.com                   mavk@lundbeck.com        
+45 36 43 24 26                     +45 36 43 30 00          



About Lundbeck

H. Lundbeck A/S (LUN.CO, LUN DC, HLUYY) is a global pharmaceutical company
specialized in brain diseases. For more than 50 years, we have been at the
forefront of research within neuroscience. Our key areas of focus are alcohol
dependence, Alzheimer's disease, bipolar disorder, depression/anxiety,
epilepsy, Huntington's disease, Parkinson's disease, schizophrenia, stroke and
symptomatic neurogenic orthostatic hypotension (NOH). 

An estimated 700 million people worldwide are living with brain disease and far
too many suffer due to inadequate treatment, discrimination, a reduced number
of working days, early retirement and other unnecessary consequences. Every
day, we strive for improved treatment and a better life for people living with
brain disease - we call this Progress in Mind. 

Read more at www.lundbeck.com/global/about-us/progress-in-mind.

Our approximately 6,000 employees in 57 countries are engaged in the entire
value chain throughout research, development, production, marketing and sales.
Our pipeline consists of several late-stage development programs and our
products are available in more 100 countries. We have research centers in
China, Denmark and the United States and production facilities in China,
Denmark, France and Italy. Lundbeck generated revenue of approximately DKK 13.5
billion in 2014 (EUR 1.8 billion; USD 2.4 billion). 

For additional information, we encourage you to visit our corporate site
www.lundbeck.com.
News Source: NASDAQ OMX



---------------------------------------------------------------------

2015-03-25 Dissemination of a Corporate News, transmitted by DGAP - a
service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de

---------------------------------------------------------------------


Language:    English          
Company:     H. Lundbeck A/S  
 
 
             Denmark          
ISIN:        DK0010287234     
 
 
End of News    DGAP News-Service  
---------------------------------------------------------------------  
337419 2015-03-25